1. Generics Bulletin
  3. >>Biosimilars

Russia’s Binnopharm Brings In Mabwell’s Adalimumab, Denosumab Biosimilars

Humira Biosimilar Approved In China; Prolia/Xgeva Rivals Pending Approvals

 
• By Dean Rudge

China’s Mabwell has furthered its strategy to bring its biosimilars to global markets “for the benefit of millions of patients around the world” via a licensing agreement with Russian player Binnopharm.

Russia’s Binnopharm will enjoy exclusive rights to develop, register, manufacture, and market Mabwell’s biosimilar Humira (adalimumab) and Prolia/Xgeva (denosumab) candidates under the terms of a licensing agreement struck between the firms covering Russia and the Eurasian Economic Union.

The Chinese biotech noted that the alliance’s target was for its Russian partner to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.